Effects of switching from Depakene to generic valproic acid on individuals with mental retardation

V. J. Vadney, K. W. Kraushaar, D. L. Coulter, T. A. Kastner

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

In an 8-week open-trial substitution study, 64 subjects with seizure disorders living at an ICF/MR were randomly assigned to either brand-named Depakene or generic Valproic Acid USP (Solvay) medication. After 4 weeks, they were switched to the other medication. Blood levels and seizures were monitored. The price of the generic Valproic Acid was less than one tenth the price of Depakene. Results show that subjects had no statistically significant changes in seizures or blood levels when the two treatment regimens were compared. These findings suggest that generic Valproic Acid USP (Solvay) may be successfully used in this population, resulting in substantial cost savings.

Original languageEnglish (US)
Pages (from-to)468-476
Number of pages9
JournalMental retardation
Volume35
Issue number6
StatePublished - Dec 1 1997

ASJC Scopus subject areas

  • Education
  • Rehabilitation
  • Health Professions(all)

Fingerprint Dive into the research topics of 'Effects of switching from Depakene to generic valproic acid on individuals with mental retardation'. Together they form a unique fingerprint.

  • Cite this

    Vadney, V. J., Kraushaar, K. W., Coulter, D. L., & Kastner, T. A. (1997). Effects of switching from Depakene to generic valproic acid on individuals with mental retardation. Mental retardation, 35(6), 468-476.